ZK 304709, the multi-target tumor growth Inhibitor™ (MTGI™), inhibits osteolysis and tumor burden in a breast cancer bone metastasis model.

被引：0
|
作者：
Käkönen, S. [1 ]
Bosslet, K. [1 ]
Siemeister, G. [1 ]
机构：
[1] Schering AG, Corp Res Oncol, Berlin, Germany
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [1] ZK 304709, the oral multi-target tumor growth inhibitor tm, inhibits primary tumor growth and metastasis formation in pancreatic tumor xenograft models.
    Siemeister, G
    Detjen, K
    Hennekes, H
    Kaekoenen, S
    Scholz, A
    Wagner, K
    Wiedenmann, B
    Bosslet, K
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9111S - 9112S
  • [2] Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709
    Siemeister, G.
    Luecking, U.
    Wagner, C.
    Detjen, K.
    Mc Coy, C.
    Bosslet, Klaus
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2006, 60 (06) : 269 - 272
  • [3] The antitumor and antimetastasis effect of the oral Multi-target Tumor Growth Inhibitor™, ZK 304709, in pancreatic tumor xenografts
    Siemeister, Gerhard
    Detjen, Katharina
    Kaekoenen, Sanna-Maria
    Luecking, Ulrich
    Mumberg, Domink
    Scholz, Arne
    Wagner, Karola
    Wiedenmann, Bertram
    Bosslet, Klaus
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [4] Synergistic effects on tumor growth inhibition by the combination of ZK 304709, the Multi-target Tumor Growth Inhibitor™, and paclitaxel or 5-FU in a mammary tumor xenograft model
    Kaekoenen, Sanna-Maria
    McCoy, Candice
    Hyman, Debra
    Luecking, Ulrich
    Bosslet, Klaus
    Siemeister, Gerhard
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [5] ZK-EPO, a third-generation epothilone inhibits tumor growth and osteolysis in a mouse model of breast cancer bone metastasis
    Kakonen, S.
    Hoffmann, J.
    Klar, U.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 35 - 35
  • [6] Phase I dose-escalation study of ZK 304709, an oral multi-target tumor growth inhibitor (MTGI), administered for 14 days of a 28-day cycle.
    Ahmed, S.
    Molife, R.
    Shaw, H.
    Steward, W.
    Thomas, A.
    Barrett, M.
    Kowal, K.
    McCoy, C.
    De-Bono, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 98S - 98S
  • [7] The oral Multi-target Tumor Growth Inhibitor™, Zk 304700, inhibits growth of pancreatic neuroendocrine tumors in an orthotopic mouse model
    Scholz, Arne
    Wagner, Karola
    Welzel, Martina
    Wiedenmann, Bertram
    Rosewicz, Stefan
    Siemeister, Gerhard
    Detjen, Katharina M.
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : A133 - A133
  • [8] Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer
    Zhu, Menghai
    Liu, Changzhen
    Li, Shifei
    Zhang, Shudong
    Yao, Qi
    Song, Qingkun
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [9] Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer
    Menghai Zhu
    Changzhen Liu
    Shifei Li
    Shudong Zhang
    Qi Yao
    Qingkun Song
    [J]. Scientific Reports, 7
  • [10] Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis
    Cher, ML
    Biliran, HR
    Bhagat, S
    Meng, YH
    Che, MX
    Lockett, J
    Abrams, J
    Fridman, R
    Zachareas, M
    Sheng, SJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (13) : 7847 - 7852
12345